Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease

MedImmune

Status and phase: Completed; Phase 1

Conditions: Graft-Versus-Host Disease; Cancer

Treatments: Drug: MEDI-507

Study type: Interventional

Funder types: Industry

Identifiers

NCT00806728

MI-CP042

Details and patient eligibility

About

A clinical trial to assess safety and two regimens of (MEDI-507) a drug given to stem cell and bone marrow recipients who have a mid-grade acute Graft-versus-Host Disease.

Full description

To assess the safety of two regimens of MEDI-507 administered to stem cell and bone marrow allograft recipients who have at least grade II acute GVHD and who have not achieved a satisfactory response to at least three days of corticosteroid therapy (2 mg/kg/day of methylprednisolone or its equivalent).

Enrollment: 17 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Allogeneic bone marrow or hematopoietic stem cell graft recipients
• Acute GVHD of at least grade II severity
• Failure of GVHD to improve on at least 2 mg/kg/day of methylprednisolone or prednisone for at least three days or recurrence of acute GVHD as corticosteroids are tapered from initial treatment of the initial episode of GVHD
• Evidence of engraftment (ANC over 1000 cells/mm3)
• Histologic evidence of GVHD from biopsy performed during the current episode
• Received GVHD prophylaxis of methotrexate, tacrolimus or cyclosporine
• Age at least 18 years
• Body weight under 130 kg
• Both males and females are eligible but females of childbearing potential will use an accepted method of avoiding pregnancy for at least 60 days after the end of treatment (which includes oral or implanted contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or a sterile sexual partner)

Exclusion criteria

• Previous receipt of MEDI-507
• Clinical or histologic manifestation of chronic GVHD
• Previous treatment with any anti-T-cell antibodies such as OKT®3 or daclizumab (Zenapax®)
• Receipt of antithymocyte globulin (ATGAM® or other ATG) since the day of transplant
• More than one allogeneic bone marrow or hematopoietic stem cell allograft
• Moribund and unlikely (in the opinion of the investigator) to survive 15 days
• Use of other investigational agents within 30 days (this does not include the use of licensed agents for indications not listed in the package insert)
• Any of the following clinical settings or diagnoses:

Ø documented or presumed significant active infection Ø pregnancy or nursing mother Ø evidence of infection with HIV-1, hepatitis B or C virus Ø hemodialysis or chronic peritoneal dialysis Ø use of a ventilator

• Histologically confirmed veno-occlusive disease of the liver
• Ascites on physical examination (this does not include small amounts of ascitic fluid detected only on ultrasound)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

17 participants in 2 patient groups

1

Experimental group

Description:

MEDI-507

Treatment:

Drug: MEDI-507

Drug: MEDI-507

2

Experimental group

Description:

MEDI-507

Treatment:

Drug: MEDI-507

Drug: MEDI-507